Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barré syndrome.

Literature DB >> 9219756

Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barré syndrome.

B C Jacobs¹, P A van Doorn, J H Groeneveld, A P Tio-Gillen, F G van der Meché.

Abstract

To investigate whether antecedent cytomegalovirus (CMV) infections in patients with Guillain-Barré syndrome are associated with the presence of specific antiganglioside antibodies, acute phase serum samples from 130 patients with Guillain-Barré syndrome and 200 controls were tested. Anti-GM2 IgM antibodies were found more often in patients with Guillain-Barré syndrome with CMV infection (22%) than in patients without the infection (2%) (P = 0.003). CMV infections may elicit anti-GM2 antibodies in susceptible patients, which may contribute to the pathogenesis of Guillain-Barré syndrome associated with CMV.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 1997 PMID： 9219756 PMCID： PMC1074154 DOI： 10.1136/jnnp.62.6.641

Source DB: PubMed Journal: J Neurol Neurosurg Psychiatry ISSN： 0022-3050 Impact factor: 10.154

14 in total

Review 1. Antibody detection in Guillain-Barré syndrome.

Authors: L Svennerholm; P Fredman
Journal: Ann Neurol Date: 1990 Impact factor: 10.422

2. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome.

Authors: B C Jacobs; P A van Doorn; P I Schmitz; A P Tio-Gillen; P Herbrink; L H Visser; H Hooijkass; F G van der Meché
Journal: Ann Neurol Date: 1996-08 Impact factor: 10.422

Review 3. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies.

Authors: F G van der Meché; P A van Doorn
Journal: Ann Neurol Date: 1995-05 Impact factor: 10.422

4. Ganglioside-like epitopes of lipopolysaccharides from Campylobacter jejuni (PEN 19) in three isolates from patients with Guillain-Barré syndrome.

Authors: N Yuki; S Handa; T Tai; M Takahashi; K Saito; Y Tsujino; T Taki
Journal: J Neurol Sci Date: 1995-05 Impact factor: 3.181

5. Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection.

Authors: S Kusunoki; A Chiba; S Hitoshi; H Takizawa; I Kanazawa
Journal: Muscle Nerve Date: 1995-04 Impact factor: 3.217

6. Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group.

Authors: L H Visser; F G van der Meché; J Meulstee; P P Rothbarth; B C Jacobs; P I Schmitz; P A van Doorn
Journal: Neurology Date: 1996-09 Impact factor: 9.910

7. Sural nerve biopsies in Guillain-Barre syndrome: axonal degeneration and macrophage-associated demyelination and absence of cytomegalovirus genome.

Authors: R Hughes; P Atkinson; P Coates; S Hall; S Leibowitz
Journal: Muscle Nerve Date: 1992-05 Impact factor: 3.217

8. Chemical structures of the core regions of Campylobacter jejuni serotypes O:1, O:4, O:23, and O:36 lipopolysaccharides.

Authors: G O Aspinall; A G McDonald; T S Raju; H Pang; A P Moran; J L Penner
Journal: Eur J Biochem Date: 1993-05-01

9. Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection.

Authors: J H Rees; N A Gregson; R A Hughes
Journal: Ann Neurol Date: 1995-11 Impact factor: 10.422

10. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure.

Authors: N Yuki; T Taki; F Inagaki; T Kasama; M Takahashi; K Saito; S Handa; T Miyatake
Journal: J Exp Med Date: 1993-11-01 Impact factor: 14.307

12 in total

Review 1. Guillain-Barré syndrome.

Authors: U Seneviratne
Journal: Postgrad Med J Date: 2000-12 Impact factor: 2.401

2. Preceding infections and anti-ganglioside antibody profiles assessed by a dot immunoassay in 306 French Guillain-Barré syndrome patients.

Authors: Christiane Caudie; Arnaud Quittard Pinon; Didier Taravel; Valérie Sivadon-Tardy; David Orlikowski; Flore Rozenberg; Tarek Sharshar; Jean Claude Raphaël; Jean Louis Gaillard
Journal: J Neurol Date: 2011-04-24 Impact factor: 4.849

10. Correlations between cytomegalovirus, Epstein-Barr virus, anti-ganglioside antibodies, electrodiagnostic findings and functional status in Guillain-Barré syndrome.

Authors: Aliakbar Taheraghdam; Peyman Pourkhanjar; Mahnaz Talebi; Mohammadreza Bonyadi; Ali Pashapour; Ehsan Sharifipour; Reza Rikhtegar
Journal: Iran J Neurol Date: 2014

Cytomegalovirus infections and anti-GM2 antibodies in Guillain-Barré syndrome.

Review 1. Antibody detection in Guillain-Barré syndrome.

2. Campylobacter jejuni infections and anti-GM1 antibodies in Guillain-Barré syndrome.

Review 3. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy: immune mechanisms and update on current therapies.

4. Ganglioside-like epitopes of lipopolysaccharides from Campylobacter jejuni (PEN 19) in three isolates from patients with Guillain-Barré syndrome.

5. Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection.

6. Cytomegalovirus infection and Guillain-Barré syndrome: the clinical, electrophysiologic, and prognostic features. Dutch Guillain-Barré Study Group.

7. Sural nerve biopsies in Guillain-Barre syndrome: axonal degeneration and macrophage-associated demyelination and absence of cytomegalovirus genome.

8. Chemical structures of the core regions of Campylobacter jejuni serotypes O:1, O:4, O:23, and O:36 lipopolysaccharides.

9. Anti-ganglioside GM1 antibodies in Guillain-Barré syndrome and their relationship to Campylobacter jejuni infection.

10. A bacterium lipopolysaccharide that elicits Guillain-Barré syndrome has a GM1 ganglioside-like structure.

Review 1. Guillain-Barré syndrome.

2. Preceding infections and anti-ganglioside antibody profiles assessed by a dot immunoassay in 306 French Guillain-Barré syndrome patients.

Review 3. Ganglioside molecular mimicry and its pathological roles in Guillain-Barré syndrome and related diseases.

Review 4. Clinical utility of autoantibodies in Guillain-Barre syndrome and its variants.

Review 5. Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis.

6. Ambiguous value of anti-ganglioside IgM autoantibodies in Guillain-Barré syndrome and its variants.

7. Association of anti-gangliosides antibodies and anti-CMV antibodies in Guillain-Barré syndrome.

Review 8. SARS-CoV-2 Infection and Guillain-Barré Syndrome: A Review on Potential Pathogenic Mechanisms.

9. A Guillain-Barré syndrome variant with prominent facial diplegia.

10. Correlations between cytomegalovirus, Epstein-Barr virus, anti-ganglioside antibodies, electrodiagnostic findings and functional status in Guillain-Barré syndrome.